Interesting questions. On NP you are essentially asking in the broad pool of executives in business , is there possibly a better CEO then NP? Of course there is but I think he is better than most for what has to happen here, with the headwinds a young biotech company has. That being said I would not pick an exec from big Pharma to be CEO of this company. Big Pharma has massive cash to build relationships in Washington and cover mistakes they make ( big Pharma has failed many a BLA) ...they also can cover their shortcomings by buying other companies. But none know how to deal with the OTC, and many have never built a young 20 employee company up. So I would avoid that type of hire.

On cash flow, this problem will be addressed in a non dilutive way, I believe...the trial data and the DCSM report tells me they will have access to more cash. Possibly from OWS but I believe e it will continue to be from banker types .